News | PET-CT | May 08, 2019

United Imaging Healthcare uPMR 790 HD TOF PET/MR Cleared by FDA

Next generation platform redefines clinical routine imaging for providers and patients

United Imaging Healthcare uPMR 790 HD TOF PET/MR Cleared by FDA

May 8, 2019 – United Imaging Healthcare (UIH), an international leader in advanced medical imaging and radiotherapy equipment, announced its U.S. Food and Drug Administration (FDA) clearance of the uPMR 790 HD TOF PET/MR. uPMR 790 redefines clinical routine imaging for PET/MR with the capability to scan a whole body within 20 minutes, balancing patient comfort with high-quality imaging. With the uPMR 790, United Imaging Healthcare demonstrates its commitment to advance precision medicine in the fields of neurology, oncology, and cardiology.

The next generation platform of the uPMR 790 delivers state-of-the-art PET and MR performance that rises above the current technology standards. The HD TOF PET platform is based on digital silicon photomultipliers (SiPMs) and lutetium-yttrium oxyorthosilicate (LYSO) crystals, offering a 2.8 mm NEMA PET spatial resolution with time-of-flight (TOF) technology and a large 32cm axial field-of-view. When this technology is combined with compressed sensing for whole body isotropic 3D MR imaging, it results in fast simultaneous whole-body PET and MR scans. This technology redefines PET/MR imaging by offering clinicians high isotropic spatial resolution to visualize small lesions while accelerating acquisition times to maximize patient comfort.

uPMR 790 also offers cutting-edge imaging for research, including theranostics and neuroscience which benefit from an increase in sensitivity, resolution, and coverage. United Imaging Healthcare’s uSync Research platform enables additional opportunities for research in areas such as simultaneous tracking of PET and MRI tracers, real-time cardiac PET/MR, functional neurological PET/MR, and multi-parametric radiometrics.

“The uPMR 790 sets a new standard for simultaneous PET and MR performance by not only enhancing the precision and resolution of scans, but by also dramatically changing the patient experience,” said Jeffrey M. Bundy, Ph.D., Chief Executive Officer of UIH Solutions. “Today’s announcement again delivers on our mission to embed breakthrough innovation across our portfolio. The uPMR is yet another proof point of our commitment to provide more patients in the United States with access to advanced technology and higher standards of care.”

For more information: www. usa.united-imaging.com

 

Related content:

FDA Clears United Imaging Healthcare uExplorer Total-Body Scanner

High-performance CTs Flood Market

Deals Proliferate in Dangerous World of CT

Related Content

Advances in long-length digital radiography are creating opportunities for visualization during spinal surgery, as well as pre- and post-operatively. Image courtesy of Fujifilm Medical Systems

Advances in long-length digital radiography are creating opportunities for visualization during spinal surgery, as well as pre- and post-operatively. Image courtesy of Fujifilm Medical Systems

Feature | Digital Radiography (DR) | July 19, 2019 | By Greg Freiherr
Recent advances in...
Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Feature | Contrast Media | July 18, 2019 | By Greg Freiherr
Macrocyclic contrast agents have the best safety profile of all the magnetic resonance (MR) contrast media that are n
AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...
FDA Approves Bayer's Gadavist Contrast for Cardiac MRI in Adult Coronary Artery Disease Patients
Technology | Contrast Media | July 15, 2019
The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic resonance...
Insightec's Exablate Neuro Approved With GE Signa Premier MRI in U.S. and Europe
News | Focused Ultrasound Therapy | July 10, 2019
GE Healthcare and Insightec announced U.S. Food and Drug Administration (FDA) approval and CE mark for Insightec’s...
Delta T1 Maps Provide Quantitative, Automated Solution to Assess Brain Tumor Burden
News | Neuro Imaging | July 05, 2019
Imaging Biometrics LLC (IB) a subsidiary of IQ-AI Ltd., is highlighting a recently published study in the American...
Medic Vision Wins Japanese PMDA Clearance for iQMR Image Reconstruction Solution
News | Magnetic Resonance Imaging (MRI) | July 05, 2019
Medic Vision Imaging Solutions announced that its 3-D iterative image reconstruction technology for shortening magnetic...
A 3-D printed model (left) and a model constructed in augmented reality (right), both of a kidney with a tumor. In both models, the kidney is clear; the tumor is visible in purple on the AR model and in white on the 3-D printed model.

A 3-D printed model (left) and a model constructed in augmented reality (right), both of a kidney with a tumor. In both models, the kidney is clear; the tumor is visible in purple on the AR model and in white on the 3-D printed model. Photo courtesy of Nicole Wake, Ph.D.

Feature | Advanced Visualization | July 02, 2019 | By Jeff Zagoudis
Three-dimensional (3-D) printing and...
Bracco Imaging Acquires Blue Earth Diagnostics
News | Radiopharmaceuticals and Tracers | July 01, 2019
Bracco Imaging S.p.A. has signed a definitive agreement to acquire Blue Earth Diagnostics, a molecular imaging company...